Safinamide in the treatment pathway of Parkinson's Disease: a European Delphi Consensus.
Journal
NPJ Parkinson's disease
ISSN: 2373-8057
Titre abrégé: NPJ Parkinsons Dis
Pays: United States
ID NLM: 101675390
Informations de publication
Date de publication:
21 Feb 2022
21 Feb 2022
Historique:
received:
14
04
2021
accepted:
22
12
2021
entrez:
22
2
2022
pubmed:
23
2
2022
medline:
23
2
2022
Statut:
epublish
Résumé
Safinamide is a highly selective, reversible MAO B-inhibitor recently marketed in European and North American countries. To better define clinical indications regarding motor and non-motor symptoms, targeted population and safety of this compound, ten movement disorders specialists, experts in their field, convened and developed a panel of statements on: the role of glutamate in Parkinson's disease, introduction to fluctuations, efficacy of safinamide on motor symptoms, motor complications and non-motor symptoms, quality of life, safety of safinamide and target population for use. Strong consensus was reached for all the statements on the efficacy of safinamide on motor symptoms, motor fluctuations, quality of life and safety. Among non-motor symptoms, a positive consensus was reached for the symptoms sleep/fatigue, mood, and pain while there was a lack of consensus for the statements regarding the efficacy of safinamide in improving cognition, urinary and sexual functions. The statement on orthostatic hypotension obtained a negative consensus. The consistent and large agreement reached in this Delphi panel perfectly reflects the perception of efficacy, safety and tolerability of safinamide as evident from pivotal trials and clinical practice and shows how these findings may guide movement disorders specialists in their clinical therapeutic approach. The impact of non-motor symptoms in PD is considerable, and management remains an unmet need. In this context, the ability of safinamide to impact some non-motor symptoms may represent the most promising and distinctive feature of this compound and deserves further investigations.
Identifiants
pubmed: 35190544
doi: 10.1038/s41531-022-00277-z
pii: 10.1038/s41531-022-00277-z
pmc: PMC8861053
doi:
Types de publication
Journal Article
Langues
eng
Pagination
17Informations de copyright
© 2022. The Author(s).
Références
Fox, S. H. Movement Disorder Society Evidence-Based Medicine Committee et al. International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson’s disease. Mov. Disord. 33, 1248–1266 (2018).
pubmed: 29570866
doi: 10.1002/mds.27372
Alborghetti, M. & Nicoletti, F. Different generations of Type-B monoamine oxidase inhibitors in Parkinson’s Disease: from bench to bedside. Curr. Neuropharmacol. 17, 861–873 (2019).
pubmed: 30160213
pmcid: 7052841
doi: 10.2174/1570159X16666180830100754
Moussa, B. H., Bakhle, Y. & Bakhle, Y. S. Monoamine oxidase: isoforms and inhibitors in Parkinson’s disease and depressive illness. Br. J. Pharmacol. 147, S287–S296 (2006).
doi: 10.1038/sj.bjp.0706464
Marzo, A. et al. Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity. Pharmacol. Res. 50, 77–85 (2004).
pubmed: 15082032
doi: 10.1016/j.phrs.2003.12.004
Chazot, P. L. Safinamide (Newron Pharmaceuticals). Curr. Opin. Investig. Drugs 2, 809–813 (2001).
pubmed: 11572661
Caccia, C. et al. Safinamide: from molecular targets to a new anti-Parkinson drug. Neurology 67, S18–S23 (2006).
pubmed: 17030736
doi: 10.1212/WNL.67.7_suppl_2.S18
Cattaneo, C. et al. Pressor response to intravenous tyramine in healthy subjects after safinamide, a novel neuroprotectant with selective, reversible monoamine oxidase B inhibition. Clin. Neuro Pharmacol. 26, 213 (2003).
Marquet, A. et al. The effect of safinamide, a novel drug for Parkinson’s disease, on pressor response to oral tyramine: a randomized, double-blind, clinical trial. Clin. Pharmacol. Ther. 92, 450–457 (2012).
pubmed: 22948897
Giossi, R. et al. Overall efficacy and safety of safinamide in Parkinson’s Disease: a systematic review and a meta-analysis. Clin Drug Investig. 41, 321–339 (2021).
pubmed: 33674954
pmcid: 8004480
doi: 10.1007/s40261-021-01011-y
Stocchi, F. & Torti, M. Adjuvant therapies for Parkinson’s disease: critical evaluation of safinamide. Drug Des. Devel Ther. 10, 609–618 (2016).
pubmed: 26917951
pmcid: 4751980
doi: 10.2147/DDDT.S77749
Kandadai, R. M., Jabeen, S. A., Kanikannan, M. A. & Borgohain, R. Safinamide for the treatment of Parkinson’s disease. Expert Rev. Clin. Pharmacol. 7, 747–759 (2014).
pubmed: 25300164
doi: 10.1586/17512433.2014.968555
Jenner, P. & Caccia, C. The role of glutamate in the healthy brain and in the pathophysiology of Parkinson’s Disease. European Neurological Review 14(Suppl.2), 2–12 (2019).
Gonzalez-Latapi, P., Bhowmick, S. S., Saranza, G. & Fox, S. H. Non-dopaminergic treatments for motor control in parkinson’s disease: an update. CNS Drugs 34(Oct), 1025–1044 (2020).
pubmed: 32785890
doi: 10.1007/s40263-020-00754-0
Stocchi, F. DEEP study group et al. Early detection of wearing off in Parkinson disease: the DEEP study. Parkinsonism Relat. Disord. 20, 204–211 (2014).
pubmed: 24275586
doi: 10.1016/j.parkreldis.2013.10.027
Stacy, M. et al. End-of-dose wearing off in Parkinson disease: a 9-question survey assessment. Clin. Neuropharmacol. 29, 312–321 (2006).
pubmed: 17095894
doi: 10.1097/01.WNF.0000232277.68501.08
Stocchi, F. et al. Study 015 Investigators. A randomized, double-blind, placebo controlled trial of safinamide as add on therapy in early Parkinson’s disease patients. Mov. Disord. 27, 106–112 (2012).
pubmed: 21913224
doi: 10.1002/mds.23954
Schapira, A. H. V. et al. Study 017 Investigators. Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson’ disease. Eur. J. Neurol. 20, 271–280 (2013).
pubmed: 22967035
doi: 10.1111/j.1468-1331.2012.03840.x
Borgohain, R. et al. Study 016 Investigators. Randomized trial of safinamide add-on to Levodopa in Parkinson’s disease with motor fluctuations. Mov. Disord. 29, 229–237 (2014).
pubmed: 24323641
doi: 10.1002/mds.25751
Borgohain, R. et al. Study 018 Investigators. Two year, randomized, controlled study of Safinamide as add-on to levodopa in mid to late Parkinson’s disease. Mov. Disord. 29, 1273–1280 (2014).
pubmed: 25044402
doi: 10.1002/mds.25961
Schapira, A. H. et al. Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial. JAMA Neurol. 74, 216–224 (2017).
pubmed: 27942720
doi: 10.1001/jamaneurol.2016.4467
Mancini, F. et al. Real life evaluation of safinamide effectiveness in Parkinson’s disease. Neurol. Sci. 39(Apr), 733–739 (2018).
pubmed: 29441484
doi: 10.1007/s10072-018-3272-y
Abbruzzese, G. et al. SYNAPSES Study Investigators Group. A European observational study to evaluate the safety and the effectiveness of safinamide in routine clinical practice: the SYNAPSES Trial. J Parkinsons Dis 11, 187–198 (2021).
pubmed: 33104040
pmcid: 7990425
doi: 10.3233/JPD-202224
Rinaldi, D. et al. The tolerability, safety and efficacy of safinamide in elderly Parkinson’s disease patients: a retrospective study. Aging Clin Exp Res. 33, 1689–1692 (2021).
pubmed: 32681474
doi: 10.1007/s40520-020-01648-3
Martí-Andrés, G. et al. Safinamide in clinical practice: a Spanish multicenter cohort study. Brain Sci. 9(Oct), 272 (2019).
pmcid: 6826846
doi: 10.3390/brainsci9100272
Cattaneo, C. et al. Long-term effects of safinamide on dyskinesia in mid-to late-stage Parkinson’s disease: a post-hoc analysis. J. Parkinsons Dis. 5, 475–481 (2015).
pubmed: 26406127
pmcid: 4923744
doi: 10.3233/JPD-150569
Blandini, F., Porter, R. H. & Greenamyre, J. T. Glutamate and Parkinson’s disease. Mol. Neurobiol. 12, 73–94 (1996).
pubmed: 8732541
doi: 10.1007/BF02740748
Chen, S. R. & Pan, H. L. Distinct roles of group III metabotropic glutamate receptors in control of nociception and dorsal horn neurons in normal and nerve-injured rats. J. Pharm. Exp. Ther. 312, 120–126 (2005).
doi: 10.1124/jpet.104.073817
Marabese, I. et al. Metabotropic glutamate receptor subtype 7 in the dorsal striatum oppositely modulates pain in sham and neuropathic rats. Neuropharmacology 135, 86–99 (2018).
pubmed: 29505788
doi: 10.1016/j.neuropharm.2018.03.003
Mao, L. M. & Wang, J. Q. Alterations in mGlu5 receptor expression and function in the striatum in a rat depression model. J. Neurochem. 145, 287–298 (2018).
pubmed: 29337350
pmcid: 5980680
doi: 10.1111/jnc.14307
Godlewska, B. R. et al. Brain glutamate in medication-free depressed patients: a proton MRS study at 7Tesla. Psychol. Med. 48, 1731–1737 (2018).
pubmed: 29224573
doi: 10.1017/S0033291717003373
Pedersen, N. P. et al. Supramammillary glutamate neurons are a key node of the arousal system. Nat. Commun. 8, 1405 (2017).
pubmed: 29123082
pmcid: 5680228
doi: 10.1038/s41467-017-01004-6
Seppi, K. et al. The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson’s disease. Mov. Disord. 26(Oct), S42–S80 (2011). Suppl 3(0 3).
pubmed: 22021174
pmcid: 4020145
doi: 10.1002/mds.23884
Cattaneo, C., Kulisevsky, J., Tubazio, V. & Castellani, P. Long-term efficacy of safinamide on parkinson’s disease chronic pain. Adv. Ther. 35, 515–522 (2018).
pubmed: 29542008
pmcid: 5910467
doi: 10.1007/s12325-018-0687-z
Cattaneo, C., Barone, P., Bonizzoni, E. & Sardina, M. Effects of safinamide on pain in fluctuating parkinson’s disease patients: a post-hoc analysis. J. Parkinsons Dis. 7, 95–101 (2017).
pubmed: 27802242
pmcid: 5302028
doi: 10.3233/JPD-160911
Geroin, C. et al. Effects of safinamide on pain in Parkinson’s disease with motor fluctuations: an exploratory study. J. Neural Transm. (Vienna). 127, 1143–1152 (2020).
pubmed: 32572581
doi: 10.1007/s00702-020-02218-7
Liguori, C., Stefani, A., Runi, R., Mercuri, N. B. & Pierantozzi, M. Safinamide effect on sleep disturbances and daytime sleepiness in motor fluctuating Parkinson’s disease patients: A validated questionnaires-controlled study. Park. Relat. Disord. 57, 80–81 (2018).
doi: 10.1016/j.parkreldis.2018.06.033
Cattaneo, C. et al. Long-term effects of safinamide on mood fluctuations in Parkinson’s Disease. J. Parkinsons Dis. 7, 629–634 (2017).
pubmed: 28777756
pmcid: 5676861
doi: 10.3233/JPD-171143
Pena, E. et al. Impact of safinamide on depressive symptoms in Parkinson’s Disease Patients (SAD-ness PD Study]: a multicenter retrospective study. Brain Sciences 11, 232 (2021).
pubmed: 33668408
pmcid: 7918129
doi: 10.3390/brainsci11020232
Bourin, M., Chenu, F. & Hascoët, M. The role of sodium channels in the mechanism of action of antidepressants and mood stabilizers. Curr. Drug Targets 10(Nov), 1052–1060 (2009).
pubmed: 19702557
doi: 10.2174/138945009789735138
Bhattacharya, A., Wickenden, A. D. & Chaplan, S. R. Sodium channel blockers for the treatment of neuropathic pain. Neurotherapeutics 6(Oct), 663–678 (2009).
pubmed: 19789071
pmcid: 5084288
doi: 10.1016/j.nurt.2009.08.001
Stocchi, F. et al. Overnight switch from rasagiline to safinamide in Parkinson’s disease patients with motor fluctuations: a tolerability and safety study. Eur. J. Neurol. 28, 349–354 (2021).
pubmed: 32961619
doi: 10.1111/ene.14552
Cattaneo, C., Jost, W. H. & Bonizzoni, E. Long-term efficacy of safinamide on symptoms severity and quality of life in fluctuating parkinson’s disease patients. J. Parkinsons Dis. 10, 89–97 (2020).
pubmed: 31594253
pmcid: 7029312
doi: 10.3233/JPD-191765
Martinez-Martin, P., Rodriguez-Blazquez, C., Forjaz, M. J. & Kurtis, M. M. Impact of pharmacotherapy on quality of life in patients with Parkinson’s Disease. CNS Drugs May 29, 397–413 (2015).
doi: 10.1007/s40263-015-0247-x
Stocchi, F. et al. A randomized, double-blind, placebo-controlled trial of safinamide as add on therapy in early Parkinson’s disease patients. Mov. Disord. 27, 106–112 (2012).
pubmed: 21913224
doi: 10.1002/mds.23954
Fowles, J. Handbook of futures research. (Greenwood Press, 1978).
Giannarou, L. & Zervas, E. Using Delphi technique to build consensus in practice. Int J. Bus. Sci. Appl Manag. 9, 65–82 (2014).
Walker, A. & Selfe, J. The Delphi method: a useful tool for the allied health researcher. Br. J. Ther. Rehabilitation. 3, 677–681 (1996).
doi: 10.12968/bjtr.1996.3.12.14731